DATROWAY (datopotamab deruxtecan-dlnk): A Trop-2-Directed ADC Newly Approved for Adults with NSCLC

On behalf of Daiichi Sankyo, Inc. and AstraZeneca, we cordially invite you
to join us for an informative discussion on:

DATROWAY (datopotamab deruxtecan-dlnk): A Trop-2-Directed ADC Newly Approved for Adults with Previously Treated Locally Advanced or Metastatic EGFR-mutated NSCLC

The main learning objectives include:
• Explore the current treatment landscape and unmet need in locally advanced or metastatic EGFRm NSCLC
• Discuss key efficacy and safety data for DATROWAY in 2L+ locally advanced or metastatic EGFRm NSCLC
• Review important dosing, administration, and adverse reaction management information for DATROWAY
• Examine patient identification and treatment considerations for DATROWAY

Faculty: Yan Ji, MD

Date/Time: August 13, 2025 at 5:30 PM

Location: Ruth's Chris Steak House
20 2nd Avenue Southwest
Rochester, Minnesota, 55902

RSVP: Christi Murphy
(612) 987-4925
christi.murphy@daiichisankyo.com